Cargando…
Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?
PURPOSE: Defined daily doses (DDD) are used for the measurement of drug utilisation. The aim of the study was to analyse whether differences between DDD and prescribed daily doses (PDD) exist for relevant drug classes such as antihypertensive drugs and, if so, whether they primarily depend on drug c...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134712/ https://www.ncbi.nlm.nih.gov/pubmed/21544512 http://dx.doi.org/10.1007/s00228-011-1014-7 |
_version_ | 1782208006668156928 |
---|---|
author | Grimmsmann, Thomas Himmel, Wolfgang |
author_facet | Grimmsmann, Thomas Himmel, Wolfgang |
author_sort | Grimmsmann, Thomas |
collection | PubMed |
description | PURPOSE: Defined daily doses (DDD) are used for the measurement of drug utilisation. The aim of the study was to analyse whether differences between DDD and prescribed daily doses (PDD) exist for relevant drug classes such as antihypertensive drugs and, if so, whether they primarily depend on drug classes or patient-related factors. METHODS: Using the data of a large German statutory health insurance scheme, we analysed continuous prescriptions for the following antihypertensive drug classes: thiazide diuretics, beta-blockers, dihydropyridine calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs). We summed the doses of all dispensed drugs per person during a defined time frame. We calculated the PDD (= total dose divided by the number of days) and expressed them as the PDD:DDD ratio (= amount of DDD per day and person). RESULTS: During the study period, 149,704 patients continuously received an antihypertensive medication. The average PDD:DDD ratio ranged from 0.84 (beta-blockers) to 1.88 (ARBs) and 2.17 (ACEIs). The average prescribed dosage of each drug class remained unchanged, even if the patients had previously received another antihypertensive drug with another PDD:DDD ratio. For example, if patients were switched from a beta-blocker to an ACEI, the PDD:DDD ratio increased, on average, from 0.79 to 2.17. Vice versa, the ratio decreased for patients with a drug change from an ACEI to a beta-blocker from 2.06 to 0.75. CONCLUSIONS: Even large differences between DDD and PDD seem to be a matter of drug classes and not primarily of patient characteristics. |
format | Online Article Text |
id | pubmed-3134712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-31347122011-08-24 Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? Grimmsmann, Thomas Himmel, Wolfgang Eur J Clin Pharmacol Pharmacoepidemiology and Prescription PURPOSE: Defined daily doses (DDD) are used for the measurement of drug utilisation. The aim of the study was to analyse whether differences between DDD and prescribed daily doses (PDD) exist for relevant drug classes such as antihypertensive drugs and, if so, whether they primarily depend on drug classes or patient-related factors. METHODS: Using the data of a large German statutory health insurance scheme, we analysed continuous prescriptions for the following antihypertensive drug classes: thiazide diuretics, beta-blockers, dihydropyridine calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs). We summed the doses of all dispensed drugs per person during a defined time frame. We calculated the PDD (= total dose divided by the number of days) and expressed them as the PDD:DDD ratio (= amount of DDD per day and person). RESULTS: During the study period, 149,704 patients continuously received an antihypertensive medication. The average PDD:DDD ratio ranged from 0.84 (beta-blockers) to 1.88 (ARBs) and 2.17 (ACEIs). The average prescribed dosage of each drug class remained unchanged, even if the patients had previously received another antihypertensive drug with another PDD:DDD ratio. For example, if patients were switched from a beta-blocker to an ACEI, the PDD:DDD ratio increased, on average, from 0.79 to 2.17. Vice versa, the ratio decreased for patients with a drug change from an ACEI to a beta-blocker from 2.06 to 0.75. CONCLUSIONS: Even large differences between DDD and PDD seem to be a matter of drug classes and not primarily of patient characteristics. Springer-Verlag 2011-03-10 2011 /pmc/articles/PMC3134712/ /pubmed/21544512 http://dx.doi.org/10.1007/s00228-011-1014-7 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Pharmacoepidemiology and Prescription Grimmsmann, Thomas Himmel, Wolfgang Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? |
title | Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? |
title_full | Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? |
title_fullStr | Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? |
title_full_unstemmed | Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? |
title_short | Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? |
title_sort | discrepancies between prescribed and defined daily doses: a matter of patients or drug classes? |
topic | Pharmacoepidemiology and Prescription |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134712/ https://www.ncbi.nlm.nih.gov/pubmed/21544512 http://dx.doi.org/10.1007/s00228-011-1014-7 |
work_keys_str_mv | AT grimmsmannthomas discrepanciesbetweenprescribedanddefineddailydosesamatterofpatientsordrugclasses AT himmelwolfgang discrepanciesbetweenprescribedanddefineddailydosesamatterofpatientsordrugclasses |